Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

NACompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
Crohn's DiseaseUlcerative ColitisInflammatory Bowel Disease
Interventions
DRUG

Vedolizumab

Trial Locations (15)

06032

Connecticut Children's Medical Center, Hartford

Unknown

Atlantic Children's Health-Goryeb Children's Hospital, Morristown

Cohen Children's Medical Center of NY, Northwell, New York

Children's Hospital of Philadelphia, Philadelphia

Hvidovre University Hospital, Copenhagen

Our Lady's Children's Hospital Crumlin, Dublin

Rambam Medical Cener, Haifa

Wolfson Medical Center, Holon

Shaare Zedek Medical Center, Jerusalem

Schneider Medical Center, Petah Tikva

Sheba Medical Center, Ramat Gan

Ichilov, Tel Aviv

Assaf Harofeh, Tzrifin

University Children's Hospital Ljubljana, Ljubljana

The Royal Hospital for Children Glasgow, Glasgow

All Listed Sponsors
lead

Shaare Zedek Medical Center

OTHER

NCT02862132 - Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases | Biotech Hunter | Biotech Hunter